Gland Pharma Receives FDA Approval for Generic Extra Strength Pataday Eye Allergy Drops
核心洞察
Gland Pharma Limited secured FDA approval for its generic version of olopatadine hydrochloride 0.7% ophthalmic solution, equivalent to Alcon's Pataday Once Daily Extra Strength (搜索).
The over-the-counter eye drops treat ocular itching associated with allergic conjunctivitis (搜索) and provide 24-hour relief with once-daily dosing.
This approval marks the second generic version of a Pataday formulation to receive FDA clearance, following Glenmark's approval for the 0.2% concentration in 2025.
Gland Pharma Limited announced on January 7 that it has received FDA approval for its abbreviated new drug application (ANDA) for olopatadine hydrochloride ophthalmic solution USP, 0.7%, marking a significant milestone for the Indian pharmaceutical company in the competitive U.S. over-the-counter eye care market.
Generic Equivalent to Extra Strength Pataday
The approved formulation is therapeutically equivalent to Alcon's Pataday Once Daily Extra Strength (搜索), an over-the-counter antihistamine eye drop that received FDA approval in 2020. The solution is indicated for temporarily relieving itchy eyes due to pollen, ragweed, grass, animal hair, and dander associated with allergic conjunctivitis (搜索).
The extra strength formulation contains a higher concentration of olopatadine hydrochloride (0.7%) compared to the standard Pataday Once Daily Relief (0.2%), which already has a generic version manufactured by Glenmark Pharmaceuticals that received FDA approval in April 2025 and launched commercially in June 2025.
Dosing and Administration
According to the product labeling, the ophthalmic solution is designed for once-daily administration, with one drop administered into each affected eye. The formulation reportedly provides symptom relief within minutes, with effects lasting 24 hours. The treatment is approved for adult and pediatric patients aged 2 and older, though physician consultation is recommended for patients under age 2.
Patients using other ophthalmic products must wait at least 5 minutes between administrations. Contact lens wearers should remove their lenses before applying the drops and wait 10 minutes before reinsertion.
Safety Considerations
The FDA approval includes specific warnings for patients to discontinue use and consult a physician if they experience eye pain, vision changes, increased eye redness, or worsening itching lasting more than 72 hours. The drops should not be used if the solution changes color or becomes cloudy, or for treating contact lens-related irritation.
Market Impact
Gland Pharma's shares closed at ₹1,710 on the National Stock Exchange on January 7, reflecting a gain of ₹16.70, or 0.99%. The company, which has been manufacturing small-molecule generic injectables since 1978 and has expanded its global footprint to over 60 countries, views this approval as validation of its expertise in developing high-quality ophthalmic formulations.
This milestone strengthens Gland Pharma's position within its ophthalmic segment and supports its broader strategy for global expansion. The approval increases accessibility and competition in the eye allergy treatment market by providing a lower-cost alternative with the same therapeutic effect as the brand-name counterpart.